Evidence map›Paper›PMID 34512721›Full record

ReviewFrontiers in genetics2021

The Emerging Role of Non-coding RNAs in Drug Resistance of Ovarian Cancer.

Hua Lan, Jing Yuan, Da Zeng, Chu Liu, Xiaohui Guo, Jiahui Yong, Xiangyang Zeng, Songshu Xiao

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Hua LanDepartment of Obstetrics and Gynecology, Third Xiangya Hospital of Central South University, Changsha, China.
Jing YuanDepartment of Obstetrics and Gynecology, Third Xiangya Hospital of Central South University, Changsha, China.
Da ZengDepartment of Obstetrics and Gynecology, Third Xiangya Hospital of Central South University, Changsha, China.
Chu LiuDepartment of Obstetrics and Gynecology, Third Xiangya Hospital of Central South University, Changsha, China.
Xiaohui GuoDepartment of Obstetrics and Gynecology, Third Xiangya Hospital of Central South University, Changsha, China.
Jiahui YongDepartment of Obstetrics and Gynecology, Third Xiangya Hospital of Central South University, Changsha, China.
Xiangyang ZengDepartment of Obstetrics and Gynecology, Third Xiangya Hospital of Central South University, Changsha, China.
Songshu XiaoDepartment of Obstetrics and Gynecology, Third Xiangya Hospital of Central South University, Changsha, China.
Central South University · CNThird Xiangya Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer is one of the most common gynecological malignancies with highest mortality rate among all gynecological malignant tumors. Advanced ovarian cancer patients can obtain a survival benefit from chemotherapy, including platinum drugs and paclitaxel. In more recent years, the administration of poly-ADP ribose polymerase inhibitor to patients with BRCA mutations has significantly improved the progression-free survival of ovarian cancer patients. Nevertheless, primary drug resistance or the acquisition of drug resistance eventually leads to treatment failure and poor outcomes for ovarian cancer patients. The mechanism underlying drug resistance in ovarian cancer is complex and has not been fully elucidated. Interestingly, different non-coding RNAs (ncRNAs), such as circular RNAs, long non-coding RNAs and microRNAs, play a critical role in the development of ovarian cancer. Accumulating evidence has indicated that ncRNAs have important regulatory roles in ovarian cancer resistance to chemotherapy reagents and targeted therapy drugs. In this review, we systematically highlight the emerging roles and the regulatory mechanisms by which ncRNAs affect ovarian cancer chemoresistance. Additionally, we suggest that ncRNAs can be considered as potential diagnostic and prognostic biomarkers as well as novel therapeutic targets for ovarian cancer.

Indexed as

circular RNAdrug resistancelong non-coding RNAmicroRNAovarian cancer

Identifiers

PMID34512721
PMCPMC8430835
OpenAlexW3197612249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.